The women’s health industry has seen advancements, but challenges still remain. Investors are often risk-averse, making it difficult for companies to secure funding. Health plans prioritize cost over clinical quality, hindering progress in areas like menopause treatment. A lack of investment in research results in conflicting data on women’s health topics, making it challenging to establish quality metrics. Furthermore, there is a lack of funding in the women’s health space, slowing down innovation and progress in this area. There is a need for more open discussion about women’s health issues to create change and provide better outcomes.
Source link
What Frustrates 3 Women’s Health Execs
